Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remigromig vs Ranibizumab in Diabetic Macular Edema
NCT06957080Phase 3Active, not recruiting
- Sponsor
- EyeBio
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) (3 arms), sponsored by EyeBio. Primary endpoint: Best-Corrected Visual Acuity at 52 weeks. Started Apr 2025; status: active, not recruiting.
02
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06957080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957080.